The latest clinical report from Prime, The evolution of GLP-1s, delves into some of the latest insights, empowering health plans, pharmacies and members with recent research, data, trends and forecasting for these medications, which are approved to treat type 2 diabetes, obesity and cardiovascular conditions
coli (originally described as Amuc_1100* and hence termed here PAS*)
GLP-1 has also been reported to promote the production of anti-inflammatory cytokines in various organs including the brain.
In Q1 2026, the per-fill cap was reported at $500, meaning patients with copays exceeding $500 would pay the difference
Sudanese Scottish author Leila Aboulela has won the 2025 PEN Pinter Prize for her fiction that explores themes of faith, migration, displacement, and the lives of Muslim women
none worked very well, and many proved dangerous